Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.645, 2012-01, pp. : 4-4
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Nilotinib, dasatinib or imatinib in CML: no clear winner
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 656, 2012-01 ,pp. :
Access to resources
Recommend
Nilotinib favourable costs over dasatinib in CML . . .
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 605, 2010-01 ,pp. :
Dasatinib/imatinib/nilotinib: Myelosuppression: case report
Reactions Weekly, Vol. 1, Iss. 1351, 2011-01 ,pp. :
Nilotinib effective in imatinib-resistant/intolerant CML
Inpharma, Vol. 1, Iss. 1575, 2007-01 ,pp. :
Dasatinib/imatinib/nilotinib: Cardiomyopathy (first report for nilotinib): case report
Reactions Weekly, Vol. 1, Iss. 1307, 2010-01 ,pp. :